Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:CSCI - Post by User

Comment by prophetoffactzon Aug 23, 2024 2:43pm
49 Views
Post# 36193831

RE:RE:RE:RE:RE:WHY NO INSIDER BUYER

RE:RE:RE:RE:RE:WHY NO INSIDER BUYERHopeforthebest: "You also are not denying my accertation that PGX scale up is a failure..."

We will hold you to it that PGX scale-up is a failure. You've been bashing the stock since the $5.40 low and the stock is up 54%. What we do know is that after multiple trial runs the 50L scale-up was judged "almost complete". The merger is now complete and Ronnie Miller says the company is now optimized to bring "transformative" products to market. PGX is now on NASDAQ - the largest biotech stage in the world. The 50L and 100L facilities "
are both expected to be completed in 2024" based to the recently released financials. A "fulsome" update is expected "shortly" from the company and could have more detail as they also expect to launch a new website soon. A comprehensive scientific article has been submitted to an influencial scientific journal(Biomaterials) for PGX-YBG/fibrosis. Potential claims for wound healing applications appear to have been substantially strengthened with the Angiogenesis Foundation. Using PGX technology, the company has successfully processed several formulations of yeast beta glucan and is now in a position to offer a very high purity YBG product with very well-defined specifications according to the 6K filing. The company has demonstrated the mechanism of action following in vitro and in vivo studies for PGX-YBG as an immune booster. The company is scheduled to showcase PGX before a conference of engineers on October 8, 2024 as a scaleable technology. With the summer holidays almost over it's time to launch the new company. If the pediatric clinical trial for the diagnostic is a success and we could find out imminently that will also shape the go-forward strategy for developing PGX and its transformative potential.

Losers nit-pick timelines.
Winners persist and in the end deliver what has never been achieved before in human history.
PGX has never been in a stronger position.


Pressurized Gas eXpanded (PGX) liquid Technology: A novel approach for scalable production of biopolymer aerogels and composites. (614)

 Tue, October 08
 Dockside 9
 Technical Session

Part of:
Biomaterials (Tuesday AM2)

Info

Affiliation:
Industry

Symposium/Topic Area:
Biomaterials

Oral or Poster Presentation:
Oral Presentation

Student Awards Eligibility:
Not a Student

Abstract Text:

We introduce a groundbreaking method for efficiently processing high-molecular-weight, water-soluble biopolymers for generating powder and fibrous aerogels as an alternative to traditional multi-step processing, including gelation, crosslinking, and lengthy solvent exchanges. This innovative technique, known as the Pressurized Gas eXpanded (PGX) liquid Technology, utilizes supercritical COexpanded ethanol to efficiently precipitate biopolymers from aqueous solutions while simultaneously removing the water from the newly formed porous structure, resulting in high-performance aerogels. The PGX process intensifies several other unit operations, such as purification, micronization and drying in a single equipment unit.

PGX process is characterized by its streamlined approach. An aqueous biopolymer solution or dispersion is co-injected with the PGX fluid through a coaxial nozzle into a collection chamber. The PGX fluid is composed of supercritical CO2 and ethanol, which facilitates the rapid precipitation of the biopolymer at moderate conditions (e.g., 40°C, 100 bar). Efficient water removal is achieved through a precisely controlled PGX fluid–water ratio within the nozzle. This manipulation steers the process away from the biphasic region, ensuring stability and ultimately leading to the formation of a well-defined biopolymer aerogel with the desired properties.    

The PGX aerogels boast remarkable properties: ultralight and highly interconnected open-pore structures with uniform, delicate features. Notably, PGX Technology achieves this on a semi-continuous basis, a feat beyond conventional methods. PGX technology extends its capabilities to the creation of innovative bioactive aerogel composites. This is achieved by combining aqueous solutions or suspensions of multiple polymers at desired ratios before undergoing PGX processing. This approach generates diverse morphologies and composite structures within the final aerogel.

Delving deeper than the fundamental principles of PGX technology, this presentation will showcase a compelling set of model aerogels. This repertoire encompasses a variety of structures, ranging from single-component biopolymeric aerogels to intricate multicomponent composites and even exfoliated nanocomposites. Furthermore, applications such as advanced wound healing dressings, innovative nutraceutical delivery systems in oral strips, and versatile bioactive delivery platforms will be discussed.


 

Pressurized Gas eXpanded (PGX) liquid Technology: A novel approach for scalable production of biopolymer aerogels and composites. (614)

 Tue, October 08
 Dockside 9
 Technical Session

Part of:
Biomaterials (Tuesday AM2)

Info

Affiliation:
Industry

Symposium/Topic Area:
Biomaterials

Oral or Poster Presentation:
Oral Presentation

Student Awards Eligibility:
Not a Student

Abstract Text:

We introduce a groundbreaking method for efficiently processing high-molecular-weight, water-soluble biopolymers for generating powder and fibrous aerogels as an alternative to traditional multi-step processing, including gelation, crosslinking, and lengthy solvent exchanges. This innovative technique, known as the Pressurized Gas eXpanded (PGX) liquid Technology, utilizes supercritical COexpanded ethanol to efficiently precipitate biopolymers from aqueous solutions while simultaneously removing the water from the newly formed porous structure, resulting in high-performance aerogels. The PGX process intensifies several other unit operations, such as purification, micronization and drying in a single equipment unit.

PGX process is characterized by its streamlined approach. An aqueous biopolymer solution or dispersion is co-injected with the PGX fluid through a coaxial nozzle into a collection chamber. The PGX fluid is composed of supercritical CO2 and ethanol, which facilitates the rapid precipitation of the biopolymer at moderate conditions (e.g., 40°C, 100 bar). Efficient water removal is achieved through a precisely controlled PGX fluid–water ratio within the nozzle. This manipulation steers the process away from the biphasic region, ensuring stability and ultimately leading to the formation of a well-defined biopolymer aerogel with the desired properties.    

The PGX aerogels boast remarkable properties: ultralight and highly interconnected open-pore structures with uniform, delicate features. Notably, PGX Technology achieves this on a semi-continuous basis, a feat beyond conventional methods. PGX technology extends its capabilities to the creation of innovative bioactive aerogel composites. This is achieved by combining aqueous solutions or suspensions of multiple polymers at desired ratios before undergoing PGX processing. This approach generates diverse morphologies and composite structures within the final aerogel.

Delving deeper than the fundamental principles of PGX technology, this presentation will showcase a compelling set of model aerogels. This repertoire encompasses a variety of structures, ranging from single-component biopolymeric aerogels to intricate multicomponent composites and even exfoliated nanocomposites. Furthermore, applications such as advanced wound healing dressings, innovative nutraceutical delivery systems in oral strips, and versatile bioactive delivery platforms will be discussed.


<< Previous
Bullboard Posts
Next >>